Bristol-Myers Squibb Co

UBS lifts Bristol‑Myers Squibb’s target price ahead of Milvexian data, boosting investor outlook on its anticoagulant pipeline and potential growth.

Explore Bristol‑Myers Squibb’s $0.63 dividend, analyst praise, and booming biliary tract cancer market – a winning mix for investors in 2026.

Explore Bristol‑Myers Squibb’s AI partnership with Microsoft—how it may reshape cancer diagnostics, analysts’ split views, and the stock’s valuation prospects.

Explore Bristol‑Myers Squibb’s rising analyst support, $60 price target bump, and 17.3% six‑month rally—why BMY’s stock may soon hit its $63.33 high.

Explore Bristol‑Myers Squibb’s value‑chance: strong cash flow, dividend yield and a high‑growth pipeline could boost the stock beyond its current volatility.

Explore how Bristol‑Myers Squibb’s FDA approval of Breyanzi for MZL is sparking a surge in shareholder value, analyst upgrades, and a promising oncology pipeline.

Explore Bristol‑Myers Squibb’s 2025 Q3 surge, new Sotyktu safety data, and bold Metsera bid—how this biopharma giant balances growth, value, and dividend returns.

Explore how Bristol‑Myers Squibb’s Q3 earnings and new Sotyktu data reveal a resilient growth engine amid patent pressure and strategic biotech moves.

Bristol-Myers Squibb’s (BMY) recent developments, including positive clinical trial results and analyst endorsements, reinforce its position as a compelling deep-value investment opportunity in the biopharmaceutical sector.

Bristol-Myers Squibb Co. reported a decrease in second-quarter profit, but exceeded market expectations, with adjusted results showing a 4.1% increase in revenue and a positive trajectory for the company.